CTIS2023-505028-74-00招募中1 期
COLchicine in BElgium in patients with coronary artery disease after Percutaneous Coronary Intervention - COL BE PCI
niversitair Ziekenhuis Gent0 个研究点目标入组 2,770 人开始时间: 2023年6月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 2,770
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age =45 years., Coronary artery disease treated with PCI and optimal medical therapy, with at least one additional risk factor (based on SMART): a. Age = year b. Diabetes mellitus, on treatment or new diagnosis with HbA1c =6.5% c. Current smoking d. Treated hypertension or lood pressure systolic = 4 mmHg or diastolic = mmHg e. Total cholesterol >240 mg/dl untreated, or treated LDL >70 mg/dl f. HDL <40 mg/dl g. hsCRP >2 mg/dl AND chronic coronary syndrome (CCS) h. eGFR <60 ml/min (MDRD) i. history of vascular disease: • CAD (PCI prior to index, CABG, MI) • stroke (ischemic or hemorrhagic) • carotid artery revascularisation • PAD (revascularisation, ABI <0.85 at rest, amputation due to atherosclerotic disease) • AAA (repair, distal aortic anteroposterior diameter >3.0cm), Able to be enrolled/randomized between 2 hour and 5 days post PCI., Written informed consent.
排除标准
- •Women who are pregnant, breastfeeding, or of childbearing potential who are not using an effective method of contraception. Or women who intend to donate oocytes., Current or planned use of any strong inhibitor of CYP3A4 or p-glycoprotein: macrolide antibiotics (clarithromycin, telithromycin), azole antifungal agents (ketoconazole, voriconazole, fluconazole, itraconazole), cyclosporine, HIV medication (ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir)., Chronic diarrhea, or inflammatory owel disease (Crohn’s disease or ulcerative colitis)., Drug or alcohol abuse., Planned coronary, carotid or peripheral revascularisation known on the day of screening., Currently enrolled in another investigational trial., Considered to be an unsuitable candidate by the investigator., Men who plan to father children during the study period or who are unwilling to use effective forms of contraception. Or men who intend to donate sperm., Any contraindication or known intolerance to colchicine., Chronic use of -or need for- colchicine., Auto-immune disease requiring current or planned chronic systemic steroids, immunosuppressant or biologic drug targeting the immune system (for example, TNF blockers, anakinra, rituximab, abatacept, tocilizumab etc.)., Creatinine clearance <30 mL/min/1.73 m2., Cirrhosis Child-Pugh stadium B and C, or acute severe liver disease, Neuromuscular disease or non-transient CK levels > 5 x ULN (unless due to MI)., History of cancer or lymphoproliferative disease within the last 3 years, other than successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma, or localized cervix carcinoma in situ.
研究者
相似试验
进行中（未招募）
1 期
Colchicine for ischemia with no obstructive coronary artery disease and microvascular dysfunctioCMDCTIS2023-507981-17-00Bispebjerg Hospital100
已完成
2 期
COCOMO-ACS Study: The Colchicine for coronary plaque modification in Acute Coronary Syndrome StudyCardiovascular - Coronary heart diseaseCoronary Artery DiseaseAcute Coronary SyndromeNon-ST elevation myocardial infarctionACTRN12618000809235South Australian Health and Medical Research Insititute64
已完成
2 期
Colchicine in Patients Undergoing Coronary Artery Bypass Grafting After Acute Coronary SyndromeCoronary Artery BypassMyocardial ReperfusionPostoperative Atrial FibrilationAcute Coronary SyndromePerioperative Myocardial InfarctionPostpericardiotomy SyndromeCoronary Artery DiseaseNCT05726019University of Sao Paulo General Hospital100
招募中
3 期
The effect of Colchicine on Cardiovascular Outcomes in Acute Coronary Syndrome Study (The COLCARDIO-ACS Study)Acute coronary syndromeAtherosclerosisACTRN12616000400460niversity of Sydney3,000
招募中
3 期
Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary InterventionCoronary Artery DiseaseNCT06095765AZ Sint-Jan AV2,770